Scarica l'app Stockscreener
79.49
1.16%
-0.93
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché LNTH Giù?
Forum
Previsione
Lantheus Holdings Inc Borsa (LNTH) Ultime notizie
How does Lantheus Holdings Inc compare to its peersLayoff News & Community Consensus Trade Alerts - baoquankhu1.vn
FDA approves Lantheus’ PYLARIFY TruVu for prostate cancer imaging - Investing.com Nigeria
Lantheus Secures Two FDA Milestones in Four Days: Lutathera Radioequivalent and PSMA PET Upgrade - Oncodaily
Lantheus Holdings (LNTH) Is Up 5.4% After New PYLARIFY TruVu And LUTATHERA ApprovalsHas The Bull Case Changed? - simplywall.st
Why Lantheus (LNTH) Is Up 5.4% After Dual FDA Wins In Radiopharmaceutical Oncology Expansion - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Is Investigating Lantheus Holdings, Inc. (LNTH) And Encourages Stockholders to Connect - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lantheus Holdings, Inc. (LNTH) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Lantheus Stock Analysis: 57% Gain Amid Revenue and Margin ConcernsNews and Statistics - IndexBox
LNTH Stock Price, Quote & Chart | LANTHEUS HOLDINGS INC (NASDAQ:LNTH) - ChartMill
Imaging & Diagnostics Stocks Decline After Q4 2025 EarningsNews and Statistics - IndexBox
Q4 Earnings Highlights: Lantheus (NASDAQ:LNTH) Vs The Rest Of The Medical Devices & SuppliesImaging, Diagnostics Stocks - Yahoo Finance
WINTON GROUP Ltd Grows Position in Lantheus Holdings, Inc. $LNTH - MarketBeat
Lantheus at Leerink Conference: Strategic Shifts and Challenges - Investing.com Nigeria
Why Lantheus Holdings stock popped by almost 12% last month - MSN
Why Lantheus Holdings Stock Popped by Almost 12% Last Month - AOL.com
Lantheus Holdings Inc (LNTH) Stock Price Up 7.21% on Mar 9 - GuruFocus
Lantheus (NASDAQ:LNTH) Trading 7.2% HigherTime to Buy? - MarketBeat
Citizens reiterates Lantheus stock rating on royalty opportunities By Investing.com - Investing.com Canada
Why Is LNTH Stock Up After Hours? - Stocktwits
(LNTH) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Lantheus Holdings, Inc. (LNTH) And Encourages Investors to Reach Out - ACCESS Newswire
Lantheus drops as Truist downgrades after Q2 miss - MSN
2026-03-08 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Lantheus Holdings, Inc. (LNTH) And Encourages Investors to Reach Out | NDAQ:LNTH | Press Release - Stockhouse
FDA approves Lantheus’ PYLARIFY TruVu for prostate cancer imaging By Investing.com - Investing.com Australia
Lantheus Holdings Q1 2025 Earnings Preview - MSN
Teachers Retirement System of The State of Kentucky Reduces Stake in Lantheus Holdings, Inc. $LNTH - MarketBeat
Wall Street Zen Upgrades Lantheus (NASDAQ:LNTH) to Strong-Buy - MarketBeat
American Century Companies Inc. Sells 341,642 Shares of Lantheus Holdings, Inc. $LNTH - MarketBeat
Lantheus Announces FDA Approval of PYLARIFY TruVu™ (piflufolastat F 18) Injection - Sahm
TD Cowen updates financial model citing upcoming Q4 results for Lantheus Holdings, Inc. (LNTH) - MSN
Lantheus (LNTH) Gains FDA Approval for New Prostate Cancer Imagi - GuruFocus
Lantheus Announces FDA Approval of PYLARIFY TruVu (piflufolastat F 18) Injection - Finviz
Lantheus Announces FDA Approval of PYLARIFY TruVu™, a New Formulation of Its PSMA PET Imaging Agent to Enhance Patient Access and Supply Capacity - Quiver Quantitative
Lantheus announces FDA approval of Pylarify TruVu (piflufolastat F 18) injection - marketscreener.com
US FDA approves Lantheus' new prostate cancer imaging formulation - Reuters
FDA OKs new PYLARIFY TruVu scan to expand prostate cancer imaging - Stock Titan
Heron Bay Capital Management Acquires New Shares in Lantheus Holdings, Inc. $LNTH - MarketBeat
Elo Mutual Pension Insurance Co Acquires New Stake in Lantheus Holdings, Inc. $LNTH - MarketBeat
Lantheus Bets On TruVu To Keep PYLARIFY Growing - Finimize
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Lantheus Holdings, Inc. (LNTH) And Encourages Stockholders to Reach Out - ACCESS Newswire
Quantbot Technologies LP Makes New Investment in Lantheus Holdings, Inc. $LNTH - MarketBeat
Equity award, tax share disposition for Lantheus (LNTH) officer - Stock Titan
Lantheus (NASDAQ: LNTH) CCO logs PSU vesting, tax withholding - Stock Titan
Lantheus Holdings (LNTH) CFO nets PSU award, withholds shares for taxes - Stock Titan
William Blair Investment Management LLC Has $29.48 Million Stake in Lantheus Holdings, Inc. $LNTH - MarketBeat
Intech Investment Management LLC Sells 33,704 Shares of Lantheus Holdings, Inc. $LNTH - MarketBeat
Lantheus receives FDA tentative approval for generic cancer drug By Investing.com - Investing.com Canada
Lantheus Holdings (LNTH): Analyst Raises Price Target to $89 | L - GuruFocus
Lantheus (LNTH) Secures FDA Tentative Nod for New Cancer Treatme - GuruFocus
Lantheus Says US FDA Tentatively Approves PNT2003 - marketscreener.com
Lantheus receives FDA tentative approval for generic cancer drug - Investing.com India
Lantheus Receives FDA Tentative Approval for Lutetium Lu 177 Dotatate (PNT2003), Radioequivalent to LUTATHERA® - The Manila Times
Lantheus Holdings, Inc. (LNTH) Stock Analysis: A Healthcare Innovator with a 21% Upside Potential - DirectorsTalk Interviews
Assessing Lantheus Holdings (LNTH) Valuation After Recent Share Price Rebound And PYLARIFY Outlook - Yahoo Finance
Lantheus Holdings, Inc. $LNTH Shares Sold by Artisan Partners Limited Partnership - MarketBeat
Lantheus Holdings (LNTH) Net Margin Decline Tests Bullish Earnings Growth Narrative - Sahm
TD Asset Management Inc Increases Stock Position in Lantheus Holdings, Inc. $LNTH - MarketBeat
Dana Investment Advisors Inc. Sells 13,875 Shares of Lantheus Holdings, Inc. $LNTH - MarketBeat
A Look At Lantheus Holdings (LNTH) Valuation After Q4 Beat And Cautious 2026 Guidance - simplywall.st
Seaport Global Upgrades LNTH to Neutral Feb 27, 2026 Lantheus Holdings, Inc - Meyka
1.15%
3.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):